FDA Panel Backs Diabetes Drug
12th Sep 2005, 07:42 GMT
Bristol-Myers and Merck should win FDA approval for a diabetes drug despite cardiovascular concerns, an agency panel said.
Latest news from WSJ.com: US Business:
- Merck's Arcoxia Draws Mixed Reviews
- Benetton Top Executives Resign
- Apple Names Rosenberg General Counsel
- Gutierrez Aims to Help U.S. Business in China
- Tyson Swings to Loss as Demand Wanes
- Eddie Bauer Agrees to Be Acquired
- Web Companies Seek Review of Fees
- Delta Cuts Bargain Fares
- Illumina to Buy Solexa for $600 Million
- BlackJack Is BlackBerry's Newest Rival